CAMBRIDGE, England & GOTHENBURG, Sweden--(BUSINESS WIRE)--Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, and OnDosis, a leader in intelligent dosing of oral solid medicines, are excited to announce a strategic collaboration.

英国剑桥和瑞典哥德堡-（商业信息）-开发用于食物过敏的口服免疫疗法治疗的先驱Camallergy和智能口服固体药物剂量领导者OnDosis很高兴宣布战略合作。

This partnership is set to transform the way food allergies (including peanut allergy) are treated, combining Camallergy's innovative therapies with OnDosis' cutting-edge Dosage Manager device technology. The drug-device combination aims to address the challenges physicians face in offering oral immunotherapy, making the treatment more accessible for patients..

这种合作关系旨在改变食物过敏（包括花生过敏）的治疗方式，将Camallergy的创新疗法与OnDosis的尖端剂量管理器设备技术相结合。药物-器械组合旨在解决医生在提供口服免疫疗法方面面临的挑战，使患者更容易获得治疗。。

A new era in oral immunotherapy

口腔免疫治疗的新纪元

Oral immunotherapy (OIT) is a proven technique to retrain the body's immune system to tolerate food allergens. It works by taking regular oral doses of the allergen, which start low and build gradually towards a maintenance dose.

口服免疫疗法（OIT）是一种经过验证的技术，可以重新训练身体的免疫系统以耐受食物过敏原。它的工作原理是定期口服剂量的过敏原，开始低，并逐渐建立维持剂量。

OnDosis brings a novel electromechanical Dosage Manager to this collaboration, replacing traditional pull-apart capsules during the ‘up-dosing’ phase. This dosing device delivers precise doses from allergen cartridges, allowing for tiny, controlled dose increments.

OnDosis为这项合作带来了一种新型机电剂量管理器，在“上剂量”阶段取代了传统的拉开胶囊。这种剂量装置提供来自过敏原药筒的精确剂量，允许微小的，受控的剂量增量。

Revolutionizing treatment and reducing burden

革命性的治疗和减轻负担

The collaboration between Camallergy and OnDosis aims to dramatically reduce the treatment burden associated with traditional oral immunotherapy. By enabling tiny, controlled dose increases, patients can eliminate the need for frequent clinic visits. Instead, the idea is for the smaller dose increments to be taken at home..

Camallergy和OnDosis之间的合作旨在显着减轻与传统口服免疫疗法相关的治疗负担。通过增加微小的受控剂量，患者可以消除频繁就诊的需要。相反，这个想法是在家里采取较小的剂量增量。。

A blend of efficacy and convenience

功效和便利的融合

At-home up-dosing aims to combine the efficacy of OIT with the convenience of other immunotherapy approaches (such as epicutaneous and sublingual).

家庭给药旨在将OIT的功效与其他免疫治疗方法（如表皮和舌下）的便利性结合起来。

Eliminating the need for up-dosing visits frees up significant time for both patients and doctors, addressing the major barrier in the uptake of OIT. It could even make the treatment suitable for adults, a customer segment currently out of reach of licensed peanut OIT.

消除了上调就诊的需要，为患者和医生节省了大量时间，解决了接受OIT的主要障碍。它甚至可以使治疗适合成年人，目前客户细分市场无法获得许可的花生OIT。

“The extra convenience will be a big selling point” said Professor Matthew Greenhawt, MD, University of Colorado School of Medicine. “Logistics in oral immunotherapy is a huge detriment, and a barrier to adoption. Moving to at-home up-dosing will bring innumerable advantages.”

科罗拉多大学医学院医学博士Matthew Greenhawt教授说：“额外的便利将是一个畅销点”。“口服免疫疗法中的物流是一个巨大的危害，也是采用的障碍。在家中增加剂量将带来无数的优势。”

Personalised treatment

个性化治疗

The partnership prioritizes individual patient needs, offering tailored treatments. Our patient-centric approach aims to smooth the treatment experience, providing a more comfortable and efficient path to desensitization.

该合作伙伴关系优先考虑个别患者的需求，提供量身定制的治疗。我们以患者为中心的方法旨在平滑治疗体验，为脱敏提供更舒适有效的途径。

Next steps

下一步

Camallergy is currently in discussions with regulatory authorities including the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) in preparation for clinical trials for peanut allergy in the UK and abroad.

Camallergy目前正在与包括英国药品和保健品监管局（MHRA）和美国食品和药物管理局（FDA）在内的监管机构进行讨论，以准备在英国和国外进行花生过敏的临床试验。

CEO statements

首席执行官声明

Sherden Timmins, CEO of Camallergy: 'This partnership with OnDosis represents a pivotal moment in our mission to tackle food allergies. By integrating our expertise in oral immunotherapy with OnDosis' cutting-edge electromechanical dosing technology, we are uniquely placed to make oral immunotherapy practical and economically viable for both patients and physicians.'.

Camallergy首席执行官Sherden Timmins：“与OnDosis的这种合作关系代表了我们应对食物过敏任务的关键时刻。通过将我们在口服免疫疗法方面的专业知识与OnDosis的尖端机电剂量技术相结合，我们具有独特的优势，可以为患者和医生提供实用且经济的口服免疫疗法。

Martin Olovsson, CEO of OnDosis: 'Collaborating with Camallergy allows us to bring our vision of precision medicine to a critical area of need. Our Dosage Manager device technology, combined with Camallergy's innovative therapies, promises to transform the landscape of food allergy treatment, aiming to make it safer and more accessible for millions worldwide.'.

OnDosis首席执行官Martin Olovsson：“与Camallergy合作使我们能够将精准医学的愿景带到一个关键的需求领域。我们的剂量管理器设备技术与Camallergy的创新疗法相结合，有望改变食物过敏治疗的格局，旨在使全球数百万人更安全，更容易获得。

About Camallergy

关于CAM过敏

Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company spun out from Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK. The company develops innovative, patient-centric treatments based on oral immunotherapy to address the tens of millions of patients worldwide living with food allergies..

Camallergy（Cambridge Allergy Ltd）是一家生物制药公司，由位于英国剑桥的剑桥大学医院NHS基金会信托基金推出。该公司开发基于口服免疫疗法的创新型，以患者为中心的治疗方法，以解决全世界数千万患有食物的患者过敏症。。

www.camallergy.com

www.camallergy.com

About OnDosis

关于OnDosis

A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage—individualized, intuitive, and intelligent—in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies.

一家瑞典生命科学公司，将彻底改变患者服药方式。这个想法是以更容易消费的形式提供个性化，直观和智能的完美剂量。OnDosis开发了一个专有技术平台，以连接的手持设备为中心，提供定制且易于调整的口服药物剂量，并实现数字技术的整合。

By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve..

通过将传统的基于药物的治疗与数字治疗相结合，OnDosis努力实现其目的：确保患者获得所需的药物，从而过上他们应得的生活。。

www.ondosis.com

翁多斯

Disclaimer

免责声明

This announcement may contain forward-looking statements about current expectations regarding future events, including the development and potential commercialisation of product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected.

本公告可能包含有关当前对未来事件的期望的前瞻性声明，包括候选产品的开发和潜在商业化。这些陈述涉及可能导致实际结果与预期结果大不相同的风险和不确定性。

The safety and efficacy of the Camallergy’s treatments are subject to confirmation in phase 3 clinical trials. They are investigational and not yet approved by regulatory agencies..

Camallergy治疗的安全性和有效性需要在3期临床试验中得到证实。他们正在调查中，尚未得到监管机构的批准。。